Page 51 - Read Online

ALHulais et al. J Cancer Metastasis Treat 2019;5:3 I http://dx.doi.org/10.20517/2394-4722.2018.71 Page 21 of 23

melanoma. Nat Commun 2017;8:1988.
144. Strizzi L, Bianco C, Normanno N, Salomon D. Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis. Oncogene
2005;24:5731-41.
145. Bianco C, Rangel MC, Castro NP, Nagaoka T, Rollman K, et al. Role of Cripto-1 in stem cell maintenance and malignant progression. Am J
Pathol 2010;177:532-40.
146. Shukla A, Ho Y, Liu X, Ryscavage A, Glick AB. Cripto-1 alters keratinocyte differentiation via blockade of transforming growth factor-
beta1 signaling: role in skin carcinogenesis. Mol Cancer Res 2008;6:509-16.
147. Yan YT, Liu JJ, Luo Y, E C, Haltiwanger RS, et al. Dual roles of cripto as a ligand and coreceptor in the nodal signaling pathway. Molecular
and Cellular Biology 2002;22:4439-49.
148. Saeki T, Stromberg K, Qi CF, Gullick WJ, Tahara E, et al. Differential immunohistochemical detection of amphiregulin and cripto in human
normal colon and colorectal tumors. Cancer Res 1992;52:3467-73.
149. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor
progression. J Mammary Gland Biol Neoplasia 2010;15:117-34.
150. Bianco C, Strizzi L, Mancino M, Rehman A, Hamada S, et al. Identification of cripto-1 as a novel serologic marker for breast and colon
cancer. Clin Cancer Res 2006;12:5158-64.
151. Rangel MC, Bertolette D, Castro NP, Klauzinska M, Cuttitta F, et al. Developmental signaling pathways regulating mammary stem cells and
contributing to the etiology of triple-negative breast cancer. Breast Cancer Res Treat 2016;156:211-26.
152. Lee KE, Simon MC. From stem cells to cancer stem cells: HIF takes the stage. Curr Opin Cell Biol 2012;24:232-5.
153. Bianco C, Cotten C, Lonardo E, Strizzi L, Baraty C, et al. Cripto-1 is required for hypoxia to induce cardiac differentiation of mouse
embryonic stem cells. Am J Pathol 2009;175:2146-58.
154. Hale AJ, Ter Steege E, den Hertog J. Recent advances in understanding the role of protein-tyrosine phosphatases in development and
disease. Dev Biol 2017;428:283-92.
155. Yang Z, Zhang C, Qi W, Cui C, Cui Y, et al. Tenascin-C as a prognostic determinant of colorectal cancer through induction of epithelial-to-
mesenchymal transition and proliferation. Exp Mol Pathol 2018;105:216-22.
156. Jang TJ, Park JB, Lee JI. The expression of CD10 and CD15 is progressively increased during colorectal cancer development. Korean J
Pathol 2013;47:340-7.
157. Pruszak J, Sonntag KC, Aung MH, Sanchez-Pernaute R, Isacson O. Markers and methods for cell sorting of human embryonic stem cell-
derived neural cell populations. Stem Cells 2007;25:2257-68.
158. Giordano G, Febbraro A, Tomaselli E, Sarnicola ML, Parcesepe P, et al. Cancer-related CD15/FUT4 overexpression decreases benefit to
agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer. J Exp Clin
Cancer Res 2015;34:108.
159. Yaji S, Manya H, Nakagawa N, Takematsu H, Endo T, et al. Major glycan structure underlying expression of the Lewis X epitope in the
developing brain is O-mannose-linked glycans on phosphacan/RPTPbeta. Glycobiology 2015;25:376-85.
160. Laczmanska I, Karpinski P, Gil J, Laczmanski L, Makowska I, et al. The PTPN13 Y2081D (T>G) (rs989902) polymorphism is associated
with an increased risk of sporadic colorectal cancer. Colorectal Dis 2017;19:O272-O8.
161. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21.
162. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci
2003;24:96-102.
163. Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor,
celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000;60:293-7.
164. Liu Y, Sun H, Hu M, Zhang Y, Chen S, et al. The role of Cyclooxygenase-2 in colorectal carcinogenesis. Clin Colorectal Cancer
2017;16:165-72.
165. Cai J, Huang L, Huang J, Kang L, Lin H, et al. Associations between the cyclooxygenase-2 expression in circulating tumor cells and the
clinicopathological features of patients with colorectal cancer. J Cell Biochem 201810.1002/jcb.27768.
166. Zhang L, Tong Y, Zhang X, Pan M, Chen S. Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon
cancer cell growth. Drug Des Devel Ther 2015;9:5851-62.
167. Dixon DA, Blanco FF, Bruno A, Patrignani P. Mechanistic aspects of COX-2 expression in colorectal neoplasia. Recent Results Cancer Res
2013;191:7-37.
168. Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010;29:781-8.
169. Hawcroft G, Ko CW, Hull MA. Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal
cancer cells. Oncogene 2007;26:3006-19.
170. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: progress and perspective. Cancer Lett
2004;215:1-20.
171. Wang D, Fu L, Sun H, Guo L, DuBois RN. Prostaglandin E2 promotes colorectal cancer stem cell expansion and metastasis in mice.
Gastroenterology 2015;149:1884-95.e4.
172. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
173. Sawaoka H, Tsuji S, Tsujii M, Gunawan ES, Sasaki Y, et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in
vivo. Lab Invest 1999;79:1469-77.
174. Ghanghas P, Jain S, Rana C, Sanyal SN. Chemoprevention of colon cancer through inhibition of angiogenesis and induction of apoptosis by
nonsteroidal anti-inflammatory drugs. J Environ Pathol Toxicol Oncol 2016;35:273-89.
175. Divvela AKC, Challa SR, Tagaram IK. Pathogenic role of cyclooxygenase-2 in cancer. J Health Sci 2010;56:502-16.
176. Xu L, Croix BS. Improving VEGF-targeted therapies through inhibition of COX-2/PGE2 signaling. Mol Cell Oncol 2014;1:e969154.
177. Leung WK, To KF, Go MY, Chan KK, Chan FK, et al. Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and